Saturday 17 October 2026
Export ZJYL’s income statement to Excel — free account
Jin Medical International Ltd.
ZJYL Healthcare Medical Instruments & Supplies
Jin Medical International Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $20.7 million, down 12.0% from fiscal 2024.
2.08
0.08
−3.70%
Follow ZJYL
| Sep '19 | Sep '20 | Sep '21 | Dec '21 | Sep '22 | Dec '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 8 | — | — | — | — | 3 | 4 |
Altman Z-Score |
— | — | — | — | — | — | 13.84 | 16.70 | 3.66 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.87 | 6.67 | 8.51 | 10.47 | 9.87 | — | 9.51 | 7.37 | 5.16 |
Beneish M-Score |
— | (2.23) | (2.81) | — | — | — | (1.78) | (1.25) | (2.46) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | (5.70) | (6.88) |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | (6.19) | 6.44 |
Quick Ratio |
1.24 | 1.07 | 1.49 | 1.96 | 1.96 | 0.00 | 2.82 | 2.06 | 1.49 |
Current Ratio |
1.83 | 1.79 | 2.38 | 3.31 | 3.31 | 0.00 | 3.49 | 2.50 | 1.86 |
Net Debt/EBITDA |
(0.10) | (0.07) | (1.93) | (1.76) | (2.84) | 0.00 | (5.40) | (6.90) | (34.79) |
Debt/Assets |
14.10% | 12.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.27 | 0.25 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.79 | 0.97 | 0.90 | 0.92 | 0.00 | 0.74 | 0.60 | 0.42 |
Operating CF/Net income |
(0.36) | 1.13 | 2.22 | 0.00 | 0.58 | 0.00 | 1.08 | (0.33) | 2.44 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | (0.11) | — | (0.46) | (4.73) | (27.24) |
Interest Coverage |
386.30 | 41.90 | 554.00 | — | — | — | — | — | — |
| 0.00% | 20.51% | 21.20% | 19.03% | 18.26% | 0.00% | 14.68% | 14.00% | 4.10% | |
| 0.00% | 10.71% | 12.32% | 12.64% | 12.93% | 27.49% | 10.69% | 9.34% | 2.40% | |
ROIC |
0.00% | 0.00% | 0.00% | 30.79% | 16.30% | 0.00% | 24.61% | 126.69% | 0.00% |
Return on Tangible Assets |
34.99% | 21.49% | 20.26% | 18.25% | 18.25% | 33.97% | 12.16% | 13.55% | 4.22% |
Average Days of Receivables |
154.59 | 177.19 | 105.11 | 78.37 | 78.37 | 0.00 | 156.00 | 132.95 | 104.34 |
Research and Development Expense of Revenue |
5.55% | 7.79% | 7.55% | 0.00% | 9.86% | — | 7.78% | 6.37% | 7.53% |
Selling, General and Administrative Expense of Revenue |
9.71% | 11.62% | 10.42% | 11.34% | 11.34% | 0.00% | 11.98% | 18.58% | 18.75% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.03 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Revenue per Share |
2.55 | 2.02 | 2.60 | 0.00 | 2.84 | — | 2.73 | 3.00 | 2.64 |
Operating CF per Share |
(0.17) | 0.31 | 0.73 | — | 0.23 | — | 0.43 | (0.15) | 0.37 |
Capex per Share |
0.00 | 0.00 | 0.00 | — | (0.01) | — | (0.01) | (0.14) | (0.85) |
Free Cash Flow per Share |
(0.17) | 0.31 | 0.73 | — | 0.23 | — | 0.41 | (0.30) | (0.48) |
Cash per Share |
0.42 | 0.35 | 0.72 | 0.00 | 1.05 | — | 2.30 | 3.42 | 3.79 |
Shareholders Equity per Share |
1.34 | 1.35 | 1.75 | 0.00 | 2.26 | — | 3.30 | 3.65 | 3.78 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.34 | 1.35 | 1.75 | 0.00 | 2.26 | — | 3.30 | 3.65 | 3.78 |
Free Cash Flow |
(1.33) | 2.50 | 5.84 | — | 1.54 | — | 3.00 | (2.33) | (3.73) |
Working Capital |
8.05 | 7.96 | 10.88 | 13.20 | 13.20 | 8.47 | 22.19 | 25.66 | 20.35 |
Capital Expenditures |
(0.07) | (0.14) | (0.04) | — | (0.04) | — | (0.10) | (1.12) | (6.63) |
Net Current Asset Value |
8.05 | 7.96 | 10.88 | 13.20 | 13.20 | 8.47 | 22.19 | 25.57 | 20.35 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.01 | 0.05 | 0.32 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.14 | 0.14 | 0.16 | 0.00 | 0.22 | — | 0.15 | 0.16 | 0.03 |
Cash ROIC |
(7.83%) | 15.37% | 29.58% | 0.00% | 6.91% | — | 7.38% | (4.21%) | (6.29%) |
Accounts Receivable Turnover |
0.00 | 1.96 | 3.00 | 3.80 | 4.66 | 0.00 | 2.34 | 2.76 | 2.86 |
Accounts Payable Turnover |
0.00 | 2.10 | 2.67 | 0.00 | 2.75 | — | 3.47 | 4.37 | 4.67 |
Inventory Turnover |
0.00 | 1.64 | 2.01 | 1.89 | 1.93 | — | 2.21 | 2.74 | 2.90 |
Average Days of Payables |
135.18 | 185.45 | 135.61 | 0.00 | 115.57 | — | 94.94 | 78.54 | 81.18 |
Days of Inventory on Hand |
162.85 | 248.11 | 178.44 | 188.92 | 188.92 | — | 141.48 | 134.89 | 122.72 |
Average Receivables |
— | 8.24 | 6.92 | 5.05 | 4.12 | 6.30 | 8.47 | 8.52 | 7.24 |
Average Payables |
— | 5.10 | 5.39 | — | 4.73 | — | 3.75 | 3.20 | 3.13 |
Average Inventory |
— | 6.50 | 7.16 | 6.88 | 6.72 | — | 5.89 | 5.11 | 5.05 |
Average Assets |
— | 20.59 | 21.36 | 21.42 | 20.94 | 10.47 | 26.92 | 39.35 | 49.58 |
Average Common Equity |
— | 10.75 | 12.42 | 14.22 | 14.82 | — | 19.61 | 26.27 | 29.06 |
Columns are period end dates